Altered neurotransmission and signal transduction: targets for nicergoline treatment.
Although we do not yet have a complete understanding of the molecular mechanisms responsible for the pathophysiology of Alzheimer's disease, it is clear that a drug such as nicergoline, which may have both acute and longer-term effects on the disease, could offer a beneficial and worthwhile approach to treatment.
Winblad
B
B
Department of Clinical Neuroscience and Family Medicine, Karolinska Institute, Huddinge University Hospital, Sweden.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology; D000242:Cyclic AMP / Q000378:metabolism*; D006801:Humans; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009530:Nicergoline / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction
D000317:Adrenergic alpha-Antagonists; D018377:Neurotransmitter Agents; D000242:Cyclic AMP; D009530:Nicergoline